Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PTPRA Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase alpha Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTPRA Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase alpha Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD36 Biologics Sequence Review Report 2026: Platelet glycoprotein 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD36 Biologics Sequence Review Report 2026: Platelet glycoprotein 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD36 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD3G Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 gamma chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD3G Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 gamma chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FCGR3A Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-A Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FCGR3A Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-A Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR3A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD55 Biologics Sequence Review Report 2026: Complement decay-accelerating factor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD55 Biologics Sequence Review Report 2026: Complement decay-accelerating factor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD55 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD69 Biologics Sequence Review Report 2026: Early activation antigen CD69 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD69 Biologics Sequence Review Report 2026: Early activation antigen CD69 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD69 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA1 Biologics Sequence Review Report 2026: Integrin alpha-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA1 Biologics Sequence Review Report 2026: Integrin alpha-1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA8 Biologics Sequence Review Report 2026: Integrin alpha-8 Similarity and Patent-Risk Signals
8 min read
ITGA8 Biologics Sequence Review Report 2026: Integrin alpha-8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD96 Biologics Sequence Review Report 2026: T-cell surface protein tactile Similarity and Patent-Risk Signals
8 min read
CD96 Biologics Sequence Review Report 2026: T-cell surface protein tactile Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD96 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAE Biologics Sequence Review Report 2026: Integrin alpha-E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAE Biologics Sequence Review Report 2026: Integrin alpha-E Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAE protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB8 Biologics Sequence Review Report 2026: Integrin beta-8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB8 Biologics Sequence Review Report 2026: Integrin beta-8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB7 Biologics Sequence Review Report 2026: Integrin beta-7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB7 Biologics Sequence Review Report 2026: Integrin beta-7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →